Gene · 3078
Papers1,634
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
261 to 280 of 1,634
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Leveraging the CSF proteome toward minimally-invasive diagnostics surveillance of brain malignancies. | Neurooncol Adv | 2022 | 36382110 | PubTator, text mining | PubMed |
| The Defensive Interactions of Prominent Infectious Protozoan Parasites: The Host's Complement System. | Biomolecules | 2022 | 36358913 | PubTator, text mining | PubMed |
| The role of the complement system in primary membranous nephropathy: A narrative review in the era of new therapeutic targets. | Front Immunol | 2022 | 36353636 | PubTator, text mining | PubMed |
| Levels of soluble complement regulators predict severity of COVID-19 symptoms. | Front Immunol | 2022 | 36330526 | PubTator, text mining | PubMed |
| Pitfalls in complement analysis: A systematic literature review of assessing complement activation. | Front Immunol | 2022 | 36330514 | PubTator, text mining | PubMed |
| Novel Complement Factor B Gene Mutation Identified in a Kidney Transplant Recipient with a Shiga Toxin-Triggered Episode of Thrombotic Microangiopathy. | Am J Case Rep | 2022 | 36306276 | PubTator, text mining | PubMed |
| Immunogenic cell death as driver of autoimmunity in granulomatosis with polyangiitis. | Front Immunol | 2022 | 36275673 | PubTator, text mining | PubMed |
| Atypical hemolytic uremic syndrome triggered by mRNA vaccination against SARS-CoV-2: Case report. | Front Immunol | 2022 | 36275662 | PubTator, text mining | PubMed |
| The OSE complotype and its clinical potential. | Front Immunol | 2022 | 36248824 | PubTator, text mining | PubMed |
| Kernel-based gene-environment interaction tests for rare variants with multiple quantitative phenotypes. | PLoS One | 2022 | 36223383 | PubTator, text mining | PubMed |
| Low Complement Factor H-Related 3 (CFHR3) Expression Indicates Poor Prognosis and Immune Regulation in Cholangiocarcinoma. | J Oncol | 2022 | 36213819 | PubTator, text mining | PubMed |
| Single-cell dissection of remodeled inflammatory ecosystem in primary and metastatic gallbladder carcinoma. | Cell Discov | 2022 | 36198671 | PubTator, text mining | PubMed |
| Pathogenic Neisseria Bind the Complement Protein CFHR5 via Outer Membrane Porins. | Infect Immun | 2022 | 36194022 | PubTator, text mining | PubMed |
| Prader-Willi syndrome, deletion subtypes, and magnesium: Potential impact on clinical findings. | Am J Med Genet A | 2022 | 36190479 | PubTator, text mining | PubMed |
| Efficacy and safety of small extracellular vesicle interventions in wound healing and skin regeneration: A systematic review and meta-analysis of animal studies. | Theranostics | 2022 | 36185607 | PubTator, text mining | PubMed |
| The human host response to monkeypox infection: a proteomic case series study. | EMBO Mol Med | 2022 | 36169042 | PubTator, text mining | PubMed |
| Clinical Utility and Potential Cost Savings of Pharmacologic Monitoring of Eculizumab for Complement-Mediated Thrombotic Microangiopathy. | Mayo Clin Proc Innov Qual Outcomes | 2022 | 36160640 | PubTator, text mining | PubMed |
| Potential gene identification and pathway crosstalk analysis of age-related macular degeneration. | Front Genet | 2022 | 36147504 | PubTator, text mining | PubMed |
| Pan-Cancer Analysis of Pentraxin 3: A Potential Biomarker of COVID-19. | Cancers (Basel) | 2022 | 36139597 | PubTator, text mining | PubMed |
| Clinical Trial Subgroup Analyses to Investigate Clinical and Immunological Outcomes of Convalescent Plasma Therapy in Severe COVID-19. | Mayo Clin Proc Innov Qual Outcomes | 2022 | 36117954 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/3078/papers?page=14